Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?
The specific binding of the dopamine antagonist 3H-spiperone to lymphocytes from a healthy control group (n = 40), a group of acute, unmedicated schizophrenic patients (n = 27), and a psychiatric control group (n = 16) was investigated. There were no differences in binding parameters between the healthy controls (Bmax 2.6 +/- 0.7 fmoles/10(6) cells; Kd 0.17 +/- 0.07 nM) and the psychiatric control group. Binding capacity of 3H-spiperone was significantly increased in lymphocytes from the schizophrenic patients (Bmax 14.4 +/- 9.3 fmoles/10(6) cells). Moreover, a slight decrease in affinity was observed (Kd 0.44 +/- 0.21 nM). Because the increase in binding appeared only in schizophrenic patients, this peripheral model could prove valuable as a diagnostic criterion.
B
B
Bondy
M
M
Ackenheil
R
R
Elbers
M
M
Fröhler
D000208:Acute Disease; D000328:Adult; D001402:B-Lymphocytes / Q000378:metabolism; D001665:Binding Sites; D002069:Butaclamol / Q000378:metabolism; D002090:Butyrophenones / Q000378:metabolism*; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D012559:Schizophrenia / Q000097:blood*; D013134:Spiperone / Q000378:metabolism*; D013601:T-Lymphocytes / Q000378:metabolism
D002090:Butyrophenones; D013134:Spiperone; D002069:Butaclamol